ALZ-801 Development

ALZ-801 Developmentalzheon2025-04-08T11:28:35-04:00

Phase 3 study evaluated efficacy of valiltramiprosate in APOE4/4 Early AD subjects

APOE4/4 homozygous

Valiltramiprosate Phase 3 trial in APOE4/4 patients with Early AD

APOLLOE4 pivotal trial enrolled 325 subjects

Valiltramiprosate development history

Valiltramiprosate Development History

*Active metabolite of valiltramiprosate, licensed by Alzheon from Bellus Health/Neurochem in 2013; Orange relates to study start date

This website uses cookies and third-party services. By clicking "ACCEPT", you confirm that you have read and are agreeing to our privacy policy and the use of ALL cookies. ACCEPT

Valiltramiprosate Phase 3 trial in APOE4/4 patients with Early AD

APOLLOE4 pivotal trial enrolled 325 subjects

Valiltramiprosate development history

*Active metabolite of valiltramiprosate, licensed by Alzheon from Bellus Health/Neurochem in 2013; Orange relates to study start date

Key Alzheon Publications